IMBdx, also known as 아이엠비디엑스, is a leading brand specializing in innovative healthcare solutions. At the core of IMBdx's offerings is their groundbreaking technology called 알파리퀴드® (AlphaLiquid®), a platform that enables fast and accurate diagnosis of hidden cancers. With 알파리퀴드®, healthcare professionals can detect and monitor cancerous cells in the bloodstream, providing valuable information for targeted therapy and treatment planning.

IMBdx offers a range of services, including comprehensive genomic profiling, known as 알파리퀴드® 100. This service allows for the simultaneous analysis of 118 cancer-related genes, facilitating the identification of actionable biomarkers and personalized treatment options. It is suitable for diagnosing various solid tumors, including lung, stomach, colon, breast, and prostate cancers.

Unlike traditional tissue biopsies, 알파리퀴드® 100 requires only a simple blood draw, making it a more convenient and less invasive option. The test's performance is backed by its high sensitivity and detection limits, ensuring accurate and reliable results. IMBdx provides their services through two methods: the 알파리퀴드® 100 Clinical Service and the 알파리퀴드® 100 Platform.

The clinical service involves collecting a blood sample, performing genomic analysis, and delivering the results within 10 business days. On the other hand, the platform allows healthcare facilities to incorporate 알파리퀴드® 100 testing in-house with the necessary equipment and support. With a focus on cutting-edge technology and personalized healthcare, IMBdx is revolutionizing cancer diagnosis and treatment, providing patients and healthcare professionals with vital insights to improve outcomes